Psychotropic and neurotropic agents in dermatology: Unapproved uses, dosages, or indications

Clinics in Dermatology

Volumn 20, Issue 5, 2002, Pages 582-594

  Koo, John Y ^a,b   Ng, Theresa C ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF HEALTH SCIENCES   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZATROPINE MESILATE; CLOMIPRAMINE; DESIPRAMINE; DEXTROPROPOXYPHENE; DIPHENHYDRAMINE; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; GABAPENTIN; HALOPERIDOL; NEUROTROPIC AGENT; NORTRIPTYLINE; OLANZAPINE; PETHIDINE; PIMOZIDE; PSYCHOTROPIC AGENT; RISPERIDONE; TRICYCLIC ANTIDEPRESSANT AGENT;

AKATHISIA; ANTICHOLINERGIC EFFECT; ATAXIA; CLINICAL TRIAL; CONSTIPATION; DELUSION; DOSE CALCULATION; DRUG INDICATION; DRUG MECHANISM; DRUG USE; EXTRAPYRAMIDAL SYMPTOM; FORMICATION; HEART DISEASE; HEART PALPITATION; HUMAN; HYPOCHONDRIASIS; INSOMNIA; NAUSEA; NEUROPATHIC PAIN; PARASITOSIS; PARESTHESIA; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; PRURITUS; PSYCHOSIS; REVIEW; RIGIDITY; SEDATION; SKIN DISEASE; SOMNOLENCE; SWEATING; TREATMENT INDICATION; TREATMENT OUTCOME; TREMOR; TRICHOTILLOMANIA; UNITED STATES; URINE RETENTION; VERTIGO; VISUAL IMPAIRMENT; XEROSTOMIA;

EID: 0036756913     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(02)00267-5     Document Type: Article

References (90)

1. Koo J.Y.M. Psychodermatology a practical manual for clinicians . Curr Probl Dermatol. 1995;204-232.
2. Munro A. Monosymptomatic hypochondriacal psychosis a diagnostic checklist based on 50 cases of the disorder . Can J Psychol. 27:1982;374-376.
3. Munro A. Monosymptomatic hypochondriacal psychosis. Br J Psychiatry. 153:1988;37-40.
4. Bishop E.R. Jr. Monosymptomatic hypochondriacal psychosis in dermatology. J Am Acad Dermatol. 9:1983;152-158.
5. Sands G.E. Three monosymptomatic hypochondriacal syndromes in dermatology. Dermatol Nurs. 8:1996;420-425.
6. Munro A. An overview of treatment in paranoia/delusional disorder. Can J Psychiatry. 40:1995;616-622.
7. Johnson G.C. Pimozide in delusions of parasitosis. J Clin Psychiatry. 44:1983;233.
8. Hamann K. Delusions of infestation treated by pimozide a double blind crossover clinical study . Acta Derm Venereol (Stockh). 62:1982;55-58.
9. Lindskov R. Delusions of infestation treated with pimozide a follow up study . Acta Derm Venereol. 65:1985;267-270.
10. Reilly T.M. The presentation and treatment of delusional parasitosis a dermatological perspective . Int Clin Psychopharmacol. 1:1986;340-353.
11. Freyne A. Delusional infestation in an elderly population. Ir Med J. 87:1994;86-88.
12. Trabert W. 100 years of delusional parasitosis. Meta-analysis of 1, 223 case reports. Psychopathology. 28:1995;238-246.
13. Opler L.A. The role of pimozide in clinical psychiatry a review . J Clin Psychiatry. 52:1991;221-233.
14. Elmer K.B., Peterson K. Therapeutic update use of risperidone for the treatment of monosymptomatic hypochondriacal psychosis . J Am Acad Dermatol. 43:2000;683-686.
15. Tennyson H. Neurotropic and psychotropic drugs in dermatology. Dermatol Clin. 19:2001.
16. Pinder R.M., Sawyer P.R. Pimozide a review of its pharmacological properties and therapeutic uses in psychiatry . Drugs. 12:1976;1-40.
17. Peroutka S.J., Greenberg D.A. Neuroleptic drug interactions with norepinephrine alpha receptor binding sites in rat brain. Neuropharmacology. 16:1977;549-556.
18. Creese I., Snyder S.H. Butyrophenone influences on the opiate receptors. Eur J Pharmacol. 36:1976;231-235.
19. Damiani J.T., Pierce D.K. Pimozide in delusions of parasitosis. J Am Acad Dermatol. 22:1990;312-313.
20. Shatzberg A.F., Degattista C. Second-generation antipsychotic medications. Manual of Clinical Psychopharmacology. 1997;154-155 APA Press.
21. Physicians' Desk Reference. 55 ed. 2001;Medical Economics Company Inc.
22. Meltzer H.Y., Lee J.C. Classification of typical and atypical antipsychotic drugs on the vasis of dopamine D1, D2, and serotonin pK values. J Pharmacol Exp Ther. 251:1989;238-246.
23. Kinon B.J. Mechanisms of action of atypical antipsychotic drugs a critical analysis . Psychopharmacology. 124:1996;2-34.
24. Richelson E. Receptor pharmacology and neuroleptics relation to clinical effects . J Clin Psychiatry. 60:1999;5-14.
25. Madhusoodanan S., Brenner R., et al. Experience with the atypical antipsychotics-risperidone and olanzapine in the elderly. Ann of Clin Psychiatry. 11:1999;113-118.
26. Gallucci G. Risperidone and the treatment of delusions of parasitosis in an elderly patient. Psychosomatics. 36:1995;578-580.
27. Cetin M., Agargun M.Y., et al. Risperidone for the treatment of monosymptomatic hypochondriacal psychosis. J Clin Psychiatry. 60:1999;554.
28. Safer D.L., WB, Roth W.T. Risperidone in the treatment of delusional parasitosis a case report . J Clin Psychopharmacol. 17:1997;131-132.
29. Weintraub E. A case of monosymptomatic hypochondriacal psychosis treated with olanzapine. Ann Clin Psychiatry. 12:2000;247-249.
30. Yorston G. Treatment of delusional parasitosis with sertindole. Int J Geriatr Psychiatry. 12:1997;1127-1128.
31. Greaves M. Pathophysiology of itching. Lancet. 348:1996;938-940.
32. Hagermark O. Peripheral and central mediators of itch. Skin Pharmacol. 55:1992;1-8.
33. Schmelz M. A neural pathway for itch. Nature Neurosci. 4:2001;9-10.
34. Rees J.L. Pruritus more scratch than itch . Clin Exp Dermatol. 24:1999;490-493.
35. Bernstein J.E., Soltani K. Inhibition of histamine-induced pruritus by topical tricyclic antidepressants. J Am Acad Dermatol. 5:1981;582-585.
36. Metze D., Beissert S., et al. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. J Am Acad Dermatol. 41:1999;533-539.
37. Arnold L.M., Mutasim D.F., et al. Characteristics of 34 adults with psychogenic excoriation. J Clin Psychiatry. 59:1998;509-514.
38. Arnold L.M., McElroy S.L. Psychogenic excoriation clinical features, proposed diagnostic criteria, epidemiology, and approaches to treatment . CNS Drugs. 15:2001;351-359.
39. Wilheim S., Deckersbach T., et al. Self-injurious skin picking clinical characteristics and comorbidity . J Clin Psychiatry. 60:1999;454-459.
40. Fruensgaard K. Neurotic excoriations a controlled psychiatric examination . Acta Psychiatr Scand. 312:(Suppl. 69):1984;1-52.
41. Gupta M.A., Haberman H.F. The self-inflicted dermatoses a critical review . Gen Hosp Psychiatry. 9:1987;45-52.
42. Gupta M. Fluoxetine is an effective treatment for neurotic excoriations a case report . Cutis. 51:1993;386-387.
43. Vittorio C.C. Treatment of habit-tic deformity with fluoxetine. Arch Dermatol. 133:1997;1203-1204.
44. Stout R.J. Fluoxetine for the treatment of compulsive facial picking. Am J Psychiatry. 147:1990;370.
45. Stein D.J., Spitz J.L., et al. Compulsive picking and obsessive-compulsive disorder. Psychosomatics. 34:1993;177-181.
46. Phillips K.A. Skin picking as a symptom of body dysmorphic disorder. Psychopharmacol Bull. 31:1995;279-288.
47. Simeon D., Gross S., et al. A double blind trial of fluoxetine in pathologic skin picking. J Clin Psychiatry. 58:1997;341-347.
48. Kalivas J., Gilman D., et al. Sertraline in the treatment of neurotic excoriations and related disorders. Arch Dermatol. 132:1996;589-590.
49. Biondi M., Petrucci R.M. Paroxetine in a case of psychogenic pruritus and neurotic excoriations. Psychother Psychosom. 69:2000;165-166.
50. Ravindran A.V., Anisman H. Obsessive-compulsive spectrum disorders effective treatment with paroxetine . Can J Psychiatry. 44:1999;805-807.
51. O'Sullivan R.L., Keuthen N.J., et al. Near-fatal skin picking from delusional body dysmorphic disorder responsive to fluvoxamine. Psychosomatics. 40:1999;79-81.
52. Arnold L.M., Dwight M.M., et al. An open clinical trial of fluvoxamine treatment of psychogenic excoriations. Clin Psychopharmaco. 19:1999;15-18.
53. Gupta M.A. Olanzapine is effective in the management of some self-induced dermatoses three case reports . Cutis. 66:2000;143-146.
54. Gupta M.A. Olanzapine may be an effective adjunctive therapy in the management of acne excoriee a case report . J Cutan Med Surg. 5:2001;25-27.
55. Duke E.E. Clinical experience with pimozide emphasis on its use in postherpetic neuralgia . J Am Acad Dermatol. 8:1983;845-850.
56. Smith K.C. Naltrexone for neurotic excoriations. J Am Acad Dermatol. 20:1989;860-861.
57. Lienemann J. Reversal of self-abusive behavior with naltrexone. J Clin Psychopharmacol. 9:1989;448-449.
58. Harris B.A., Flowers F.P. Improvement of chronic neurotic excoriations with oral doxepin therapy. Int J Dermatol. 26:1987;541-543.
59. Gupta M.A., Haberman H.F. Neurotic Excoriations a review and some new perspectives . Comprehensive Psychiatry. 27:1986;381-386.
60. Swedo S., Rapoport J., Lenane M., et al. A double blind comparison of clomipramine and desipramine in the treatment of trichotillomania. N Engl J Med. 321:1989;497-501.
61. Winchel R., Stanley B., et al. Clinical characteristics of trichotillomania and its response to fluoxetine. J Clin Psychiatry. 53:1992;304-308.
62. Cooper J. The leyton obsessional inventory. Psychol Med. 1:1970;48-64.
63. Swedo S.E., Leonard H.L., et al., Regional cerebral glucose metabolism in women with trichotillomania. Arch Gen Psychiatry. 48:1991;828-833.
64. Swedo S.E., Rapoport J., Lenane M., et al. A double blind comparison of clomipramine and desipramine in the treatment of trichotillomania. N Engl J Med. 321:1989;497-501.
65. Stanley M., Swann A., Freeman E., Reich L. Fluvoxamine treatment of trichotillomania. J Clin Psychopharmacol. 17:1997;278-283.
66. Christenson G., Mitchell J., Callies A. A placebo-controlled, double blind crossover study of fluoxetine in trichotillomania. Am J Psychiatry. 148:1991;1566-1570.
67. Streichenwein S. A long term, double blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. Am J Psychiatry. 152:1995;1192-1196.
68. Potenza M., Epperson C.N., et al. Olanzapine augmentation of Fluoxetine in the treatment of trichotillomania. Am J Psychiatry. 155:1998;1299-1300.
69. Gabriel A. A case of resistant trichotillomania treated with risperidone-augmented fluvoxamine. Can J Psychiatry. 46:2001;285-286.
70. Epperson C.N., Wasylink S., et al. Risperidone addition in serotonin reuptake inhibitor-resistant trichotillomania three cases . J Child Adolesc Psychopharmacol. 9:1999;43-49.
71. Stein D.J., Hawkridge S., Emsley R.A. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. J Clin Psychiatry. 58:1997;119-122.
72. Stein D.J. Low-dose pimozide augmentation of serotonin reuptake blockers in the treatment of trichotillomania. J Clin Psychiatry. 53:1992;123-126.
73. CPN W. A new treatment for postherpetic neuralgia. N Engl J Med. 343:2000;1563-1565.
74. Choo P.W., Donahue J.G., Walker A.M., et al. Risk factors for postherpetic neuralgia. Arch Intern Med. 157:1997;1217-1224.
75. Ragozzino M.W., Kurland L.T., et al. Population-based study of herpes zoster and its sequelae. Medicine. 61:1982;310-316.
76. Beydoun A. Postherpetic neuralgia role of gabapentin and other treatment modalities . Epilepsia. 40:1999;S51-S56.
77. Bowsher D. The effects of pre-emptive treatment of postherpetic neuralgia with amitriptyline a randomized, double-blind placebo-controlled trial . J Pain Symptom Manage. 13:1997;327-331.
78. Kishore-Kumar R., Schafer S., et al. Desipramine relieves postherpetic neuralgia. Clin Pharmacol Ther. 47:1990;305-312.
79. Max M.B., Culnane M., et al. Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology. 38:1988;1427-1432.
80. Watson C.P., Chipman M., et al. Nortriptyline versus amitriptyline in postherpetic neuralgia a randomized trial . Am Acad Neurol. 51:1998;1166-1172.
81. Bowsher D. Postherpetic neuralgia and its treatment a retrospective survey of 191 patients . J Pain Symptom Manage. 12:1996;290-299.
82. Nicholson B. Gabapentin use in neuropathic pain syndromes. Acta Neurol Scand. 101:2000;359-371.
83. Rowbotham M., Stacey B., et al. Gabapentin for the treatment of postherpetic neuralgia a randomized controlled trial . J Am Med Assoc. 280:1998;1837-1842.
84. Segal A. Gabapentin as a novel treatment for postherpetic neuralgia. Am Acad Neurology. 1996;1175-1176.
85. Filadora V.A., Lema M.J. Acute herpetic neuralgia and postherpetic neuralgia in the head and neck response to gabapentin in five cases . Reg Anesth Pain Med. 24:1999;170-174.
86. Mellick G.A. Reflex sympathetic dystrophy with gabapen-tin. Arch Phys Med Rehabil. 78:1997;98-105.
87. Solaro C., Capello E., et al. An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients. Neurology. 51:1998;609-611.
88. Khan O.A. Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients. Neurology. 51:1998;611-614.
89. Sist T., Miner M., Lema M. Gabapentin for idiopathic trigeminal neuralgia report of two cases . Neurology. 48:1997;1467-1471.
90. Collins S., McQuay H., et al. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia a quantitative systematic review . J Pain Symptom Manage. 20:2000;449-458.